Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Patients With Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer

NCT04732598 is registered in ClinicalTrials.gov with Japanese Foundation for Cancer Research as lead sponsor.

NCT NCT04732598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04732598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Patients With Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer
Lead sponsor
Japanese Foundation for Cancer Research
Phase
Phase 3
Overall status
Completed
Start date
January 21, 2021
Completion date
March 13, 2026
Enrollment
281 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer